Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-17
2007-07-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000, C514S234200, C514S260100, C540S504000, C540S460000, C540S575000, C540S492000, C544S278000, C544S117000
Reexamination Certificate
active
10497382
ABSTRACT:
The present invention relates to furanopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 5124331 (1992-06-01), Arita et al.
patent: 884 310 (1998-12-01), None
patent: WO 01 030768 (2001-05-01), None
patent: WO 01 74344 (2001-10-01), None
Coleman, P.J.; Fraley, M. E.; Expert. Opin. Ther. Patents; 2001; 14(12); 1659-1667.
Cancer Management: A Multidisciplinary Approach, Publishers of Oncology, 2005-2006, 9thEdition, Chapter 26, 615-638.
Cancer Research 64, pp. 3276-3280, May 1, 2004, by R. Sakowicz, et al.
Org. Chem. Incl. Med. Chem., vol. 20B, No. 9, pp. 780-783, 1981, V. P. Vaidya, et al.
Biochemistry, vol. 42, No. 2, pp. 338-349, 2003, S.Debonis, et al.
Fraley Mark E.
Hartman George D.
Beeler Nicole M.
Berch Mark L.
Merck & Co. , Inc.
Moore Susanna
Muthard David A.
LandOfFree
Substituted furopyrimidinones as a mitotic kinesin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted furopyrimidinones as a mitotic kinesin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted furopyrimidinones as a mitotic kinesin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740554